Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...

Here's how an activist investor is threatening a Peninsula drug maker's merger plans. And the drama introduces a potential ...

Tempus AI (TEM) and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced a new collaboration. The two companies ...

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...